Benefits
Bone density: mixed results, no fracture data
Vitamin K2 MK-7 activates osteocalcin, the protein that binds calcium and incorporates it into hydroxyapatite crystal in bone matrix. Human results are mixed. The 3-year placebo-controlled trial cited on this page, in postmenopausal women with osteopenia, did not significantly improve bone mineral density or bone microarchitecture compared with placebo. A separate 1-year study in middle-aged and older Chinese adults found that low-dose MK-7 helped maintain lumbar-spine bone density versus a control group, but that study used an open-label control design and the effect was modest. Neither study used K2Quest®, and no cited trial measured whether people broke fewer bones.
Arterial calcification: what the cited trials found
Matrix Gla protein (MGP) is the body's primary inhibitor of vascular calcification — but it requires Vitamin K2 to become activated (carboxylated). When K2 is low, more MGP stays in its inactive form, and researchers have proposed that this lets calcium build up in artery walls. The cited human research is much thinner than that idea suggests, and both cardiovascular studies were done in people on chronic hemodialysis, not in healthy adults. One was a short dose-finding study showing that higher MK-7 doses activated more matrix Gla protein, which is a blood marker rather than a heart outcome. The other, a 24-week randomized trial of 375 mcg/day in 96 hemodialysis patients, missed its main endpoint: there was no significant difference in arterial stiffness measured by carotid-femoral pulse wave velocity (p=0.24). A benefit appeared only in the subgroup who also had diabetes, which points to a question for future research rather than proving an effect.
PMS symptom management
None of the studies cited on this page looked at PMS, menstrual cramps, mood, bloating, or progesterone. The idea that vitamin K2 eases PMS symptoms is not supported by any reference listed here, so it should not be a reason to choose this ingredient.
Mechanism of action
Carboxylation of Gla-proteins: osteocalcin and MGP activation
Vitamin K2 serves as the essential cofactor for gamma-glutamyl carboxylase — the enzyme that carboxylates (activates) Gla-domain proteins including osteocalcin and matrix Gla protein (MGP). Carboxylated osteocalcin binds hydroxyapatite (bone mineral) and calcium ions, anchoring them in bone matrix for density and strength. Carboxylated MGP actively chelates calcium ions in vessel walls and inhibits vascular smooth muscle calcification. When K2 intake is low, more of both proteins stay in the inactive (undercarboxylated) form. Population studies have linked higher K2 intake with better bone and heart measures, but those are associations, not proof that taking a K2 supplement changes what happens to a person, and the trials cited on this page did not consistently show that it does.
Clinical trials
This card describes a 3-year randomized, double-blind, placebo-controlled trial of MK-7 (180 mcg/day) versus placebo in 244 healthy postmenopausal women, attributed to Knapen and colleagues, 2013. Important caveat: that study is not in this page's reference list and has no PubMed link here, so a reader cannot check it. The 3-year trial that is cited on this page (Ronn 2021, PMID 33030563, in postmenopausal women with osteopenia) did not find a significant bone density benefit.
244 healthy postmenopausal women. 3-year intervention.
The reported result was that MK-7 preserved bone mineral density at the lumbar spine and femoral neck compared with placebo. Because this trial is not among the references on this page, treat those figures as unverified here, and weigh them against the cited 3-year trial in women with osteopenia that found no significant difference from placebo. Context worth keeping in mind: Pharmaceutical bisphosphonates (alendronate, zoledronate) and denosumab produce larger BMD increases (~3-7% over 3 years) and have direct fracture reduction evidence. MK-7 is a reasonable adjunctive bone health intervention for healthy postmenopausal women, not a substitute for established osteoporosis pharmacotherapy.